A
Amy A. Pruitt
Researcher at University of Pennsylvania
Publications - 40
Citations - 1887
Amy A. Pruitt is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Transplantation & Immunosuppression. The author has an hindex of 18, co-authored 39 publications receiving 1659 citations.
Papers
More filters
Journal ArticleDOI
Assumptions in the radiotherapy of glioblastoma
Fred H. Hochberg,Amy A. Pruitt +1 more
TL;DR: CT scan accuracy may permit smaller-field and higher-dose irradiation therapy for glioblastoma, and current radiation doses would appear to be inadequate for therapy of the primary tumor.
Journal ArticleDOI
The Spinal Cord: A Review of Functional Neuroanatomy
TL;DR: In this article, anatomic structures are correlated with relevant clinical signs and symptoms and a step-wise approach to spinal cord diagnosis is outlined, which is essential for interpretation of clinical signs, and for understanding of pathologic processes involving the spinal cord.
Journal ArticleDOI
Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases
Santosh Kesari,Santosh Kesari,Ryung S. Kim,Vassilios Markos,Jan Drappatz,Jan Drappatz,Patrick Y. Wen,Patrick Y. Wen,Amy A. Pruitt +8 more
TL;DR: These patients have a better prognosis than children with BSGs reported in the literature and call for larger prospective studies to fully assess the importance of these factors in the clinical setting and to help stratify patients in future clinical studies.
Journal ArticleDOI
Neurological complications of transplantation: part I: hematopoietic cell transplantation.
TL;DR: This 2 part review emphasizes a practical consultative approach to central and peripheral nervous system problems related to HCT or SOT with clinical and neuroimaging examples from the authors’ institutional experience.
Journal ArticleDOI
Analysis of the treatment of neuromyelitis optica.
Jose Torres,Amy A. Pruitt,Laura J. Balcer,Steven L. Galetta,Clyde E. Markowitz,Nabila Dahodwala +5 more
TL;DR: Rituximab significantly reduces relapse rates and improves disability while maintaining comparable tolerability to other immunosuppressive treatments for NMO.